The clinical diagnosis of AD is primarily based on physiological biomarkers, including the presence of Amyloid-β (Aβ) plaques, alterations in cerebrospinal fluid, p-tau, and structural atrophy in MTL, all of which correspond to the ATN framework (Amyloid, Tau, Neurodegeneration)9,10. This evidence concerns the gene MAPT and Alzheimer disease.